860 related articles for article (PubMed ID: 32271431)
81. LncRNA CASC2 inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation and migration by regulating the miR-222/ING5 axis.
Han Y; Liu Y; Yang C; Gao C; Guo X; Cheng J
Cell Mol Biol Lett; 2020; 25():21. PubMed ID: 32206065
[TBL] [Abstract][Full Text] [Related]
82. CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR-18a-5p/FIH1 axis.
Liu QY; Gao LY; Xu L; Zhang XL; Zhang LJ; Gong XL; Luo SB; Zhao R; Cheng RC
Kaohsiung J Med Sci; 2021 Apr; 37(4):268-275. PubMed ID: 33336500
[TBL] [Abstract][Full Text] [Related]
83. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
[TBL] [Abstract][Full Text] [Related]
84. circANKRD28 inhibits cisplatin resistance in non-small-cell lung cancer through the miR-221-3p/SOCS3 axis.
Song S; Shi Y; Zeng D; Xu J; Yang Y; Guo W; Zheng Y; Tang H
J Gene Med; 2023 Apr; 25(4):e3478. PubMed ID: 36740786
[TBL] [Abstract][Full Text] [Related]
85. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
[TBL] [Abstract][Full Text] [Related]
86. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370.
Liu AM; Zhu Y; Huang ZW; Lei L; Fu SZ; Chen Y
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5802-5814. PubMed ID: 31298332
[TBL] [Abstract][Full Text] [Related]
87. RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis.
Yang L; Zhang Y; Ling C; Heng W
Biotechnol Lett; 2018 Mar; 40(3):543-550. PubMed ID: 29288351
[TBL] [Abstract][Full Text] [Related]
88. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
89. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
90. Upregulated lncRNA CASC2 May Inhibit Malignant Melanoma Development Through Regulating miR-18a-5p/RUNX1.
Zhang Y; Qian W; Feng F; Cao Q; Li Y; Hou Y; Zhang L; Fan J
Oncol Res; 2019 Feb; 27(3):371-377. PubMed ID: 29422114
[TBL] [Abstract][Full Text] [Related]
91. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
Jin D; Wu Y; Shao C; Gao Y; Wang D; Guo J
Oncol Rep; 2018 Aug; 40(2):609-620. PubMed ID: 29901163
[TBL] [Abstract][Full Text] [Related]
92. Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5.
Hao GJ; Ding YH; Wen H; Li XF; Zhang W; Su HY; Liu DM; Xie NL
Biochem Biophys Res Commun; 2017 Jul; 488(3):501-508. PubMed ID: 28511796
[TBL] [Abstract][Full Text] [Related]
93. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
94. Long non-coding RNA MIR155HG knockdown suppresses cell proliferation, migration and invasion in NSCLC by upregulating TP53INP1 directly targeted by miR-155-3p and miR-155-5p.
Ren XY; Han YD; Lin Q
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4822-4835. PubMed ID: 32432745
[TBL] [Abstract][Full Text] [Related]
95. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
96. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
97. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
98. miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.
Sun Z; Ren M; Niu J; Tang G; Li Y; Kong F; Song X
Environ Toxicol; 2024 Jul; 39(7):3956-3966. PubMed ID: 38587027
[TBL] [Abstract][Full Text] [Related]
99. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
[TBL] [Abstract][Full Text] [Related]
100. DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p.
Li C; Chen L; Song W; Peng B; Zhu J; Fang L
Acta Histochem; 2021 Oct; 123(7):151788. PubMed ID: 34543777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
